Helsinn Healthcare - Articles and news items

EMA to review Helsinn’s anamorelin HCI marketing authorisation application

Industry news / 30 November 2015 /

The European Medicines Agency (EMA) has accepted for review, the marketing authorisation application (MAA) for Helsinn Group’s anamorelin HCI…

Aloxi needle

European Commission approves ALOXI injection to prevent nausea and vomiting due to chemotherapy in children as young as one month

Industry news / 27 May 2015 / Victoria White

Helsinn Group has announced that the European Commission has approved ALOXI injection for the prevention of acute CINV in children aged one to six months…


Helsinn announces that pivotal Phase III trial data for Anamorelin in ROMANA 1 and 2 studies in non-small cell lung cancer patients with anorexia-cachexia will be presented at the 38th European Society for Medical Oncology (ESMO) Congress in 2014

Industry news / 25 September 2014 / Helsinn

Helsinn Group announces that Phase III data from the largest trial program of its kind to date in anamorelin, a novel, once-daily ghrelin receptor agonist in development for cancer-anorexia-cachexia (CACS) in non-small cell lung cancer will be presented at the 38th European Society for Medical Oncology Congress…

Zealand Pharma Receives Milestone Payment from Helsinn Healthcare

Industry news, News / 9 December 2010 / M:Communications

Zealand Pharma, today announces the receipt of a EUR 500,000 milestone payment as part of its license agreement with Helsinn Healthcare…


The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...